中紅醫療(300981.SZ):與上藥控股簽訂戰略合作框架協議
格隆匯9月14日丨中紅醫療(300981.SZ)公佈,公司作為乙方與上藥控股有限公司作為甲方於2022年9月14日簽署了《戰略合作框架協議》。鑑於乙方擴展業務之需求,甲方利用其在醫藥分銷、藥品倉儲、物流等方面的優勢,達成合作方案如下:
1、乙方將根據自身業務需求,委託甲方為其集團公司及下屬控股企業生產的產品提供物流配送服務,或承租甲方物流倉庫,委託甲方對其產品進行庫存管理。
2、乙方將根據市場情況,同等條件下優先考慮將其集團公司及下屬控股企業生產的產品的經銷權授予甲方;甲方將根據市場情況,同等條件下優先考慮選擇乙方及下屬控股企業生產的產品,利用其全國分銷業務網絡,負責在授權區域內的配送。
公司表示,通過該次作,能夠不斷提升公司核心競爭力,進一步協同擴展公司產品銷售渠道,有利於發展壯大主營業務,符合公司長遠戰略規劃。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.